125 related articles for article (PubMed ID: 12732352)
1. Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa.
Liang AM; Light DR; Kochanny M; Rumennik G; Trinh L; Lentz D; Post J; Morser J; Snider M
Biochem Pharmacol; 2003 May; 65(9):1407-18. PubMed ID: 12732352
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.
Chou YL; Davey DD; Eagen KA; Griedel BD; Karanjawala R; Phillips GB; Sacchi KL; Shaw KJ; Wu SC; Lentz D; Liang AM; Trinh L; Morrissey MM; Kochanny MJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):507-11. PubMed ID: 12565961
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of two potent nonamidine inhibitors bound to factor Xa.
Adler M; Kochanny MJ; Ye B; Rumennik G; Light DR; Biancalana S; Whitlow M
Biochemistry; 2002 Dec; 41(52):15514-23. PubMed ID: 12501180
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of factor Xa by a peptidyl-alpha-ketothiazole involves two steps. Evidence for a stabilizing conformational change.
Betz A; Wong PW; Sinha U
Biochemistry; 1999 Nov; 38(44):14582-91. PubMed ID: 10545181
[TBL] [Abstract][Full Text] [Related]
6. Complementary DNA cloning and kinetic characterization of a novel intracellular serine proteinase inhibitor: mechanism of action with trypsin and factor Xa as model proteinases.
Morgenstern KA; Sprecher C; Holth L; Foster D; Grant FJ; Ching A; Kisiel W
Biochemistry; 1994 Mar; 33(11):3432-41. PubMed ID: 8136380
[TBL] [Abstract][Full Text] [Related]
7. Kinetic characterization of factor Xa binding using a quenched fluorescent substrate based on the reactive site of factor Xa inhibitor from Bauhinia ungulata seeds.
Oliva ML; Andrade SA; Juliano MA; Sallai RC; Torquato RJ; Sampaio MU; Pott VJ; Sampaio CA
Curr Med Chem; 2003 Jul; 10(13):1085-93. PubMed ID: 12678803
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
[TBL] [Abstract][Full Text] [Related]
9. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
10. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
11. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human coagulation factor xa. Studies on catalytic efficiency and inhibitor binding.
Underwood MC; Zhong D; Mathur A; Heyduk T; Bajaj SP
J Biol Chem; 2000 Nov; 275(47):36876-84. PubMed ID: 10973949
[TBL] [Abstract][Full Text] [Related]
13. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
[TBL] [Abstract][Full Text] [Related]
14. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site.
Dunwiddie C; Thornberry NA; Bull HG; Sardana M; Friedman PA; Jacobs JW; Simpson E
J Biol Chem; 1989 Oct; 264(28):16694-9. PubMed ID: 2777803
[TBL] [Abstract][Full Text] [Related]
15. Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Liang G; Bowen JP
Curr Top Med Chem; 2016; 16(13):1506-29. PubMed ID: 26369819
[TBL] [Abstract][Full Text] [Related]
16. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor.
Franssen J; Salemink I; Willems GM; Wun TC; Hemker HC; Lindhout T
Biochem J; 1997 Apr; 323 ( Pt 1)(Pt 1):33-7. PubMed ID: 9173898
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the active site caging of serine proteases: thrombin and factor Xa.
Thuring JW; Li H; Porter NA
Biochemistry; 2002 Feb; 41(6):2002-13. PubMed ID: 11827547
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Adler M; Davey DD; Phillips GB; Kim SH; Jancarik J; Rumennik G; Light DR; Whitlow M
Biochemistry; 2000 Oct; 39(41):12534-42. PubMed ID: 11027132
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.
Guilford WJ; Shaw KJ; Dallas JL; Koovakkat S; Lee W; Liang A; Light DR; McCarrick MA; Whitlow M; Ye B; Morrissey MM
J Med Chem; 1999 Dec; 42(26):5415-25. PubMed ID: 10639283
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the prothrombinase complex: factor Va alters macromolecular recognition of a tick anticoagulant peptide mutant by factor Xa.
Betz A; Vlasuk GP; Bergum PW; Krishnaswamy S
Biochemistry; 1997 Jan; 36(1):181-91. PubMed ID: 8993332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
